Gilead's Veklury shows in vitro activity against ten SARS‑CoV‑2 variants - Clinical Trials Arena

Retrieved on: 2022-02-14 13:52:34

Tags for this article:

Click the tags to see associated articles and topics

Gilead's Veklury shows in vitro activity against ten SARS‑CoV‑2 variants - Clinical Trials Arena. View article details on hiswai:

Excerpt

Gilead Sciences has reported that Veklury (remdesivir) showed to retain antiviral activity against ten variants, including Omicron.

Article found on: www.clinicaltrialsarena.com